This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (50)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Further Clinical and Laboratory Assessment

Robert E. Weibel, MD; Barbara J. Kuter, MPH; Beverly J. Neff, PhD; Carol A. Rothenberger, RN; Alison J. Fitzgerald, BSN; Karen A. Connor, BSN, PNP; David Morton, BS; Arlene A. McLean, PhD; Edward M. Scolnick, MD

JAMA. 1985;254(17):2435-2439.

Abstract
A clinical trial among 137 healthy children, ages 1 to 12 years, was conducted with four different doses (4,350, 870, 435, and 43 plaque-forming units [pfu]) of live Oka/Merck varicella vaccine to evaluate clinical reactions and selected laboratory parameters and to determine the minimum effective dose and induction time of antibody. The vaccine was well tolerated with no significant difference in the rate of reported symptoms by dose. The frequency of varicellalike rash was 3% (4/137); all rashes were mild. Serum aminotransferase values were essentially unchanged after vaccination. Minor variations found in platelet counts after vaccination were not associated with any bleeding, bruising, or clotting. Among initially seronegative children who received doses of 435 pfu or greater, 94% assayed at two weeks and 100% assayed at four or six weeks seroconverted. The geometric mean titers were similar for all four doses at six weeks. IgG and IgA responses were demonstrated with no relation to the vaccine dose.

(JAMA 1985;254:2435-2439)

Author Affiliations
From the Department of Pediatrics, University of Pennsylvania, Philadelphia (Dr Weibel and Mss Rothenberger, Fitzgerald, and Connor); and the Department of Virus and Cell Biology Research, Merck Sharp & Dohme Research Laboratories, West Point, Pa (Ms Kuter, Drs Neff, McLean, and Scolnick, and Mr Morton).

Footnotes
Reprint requests to Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, 34th Street and Civic Center Boulevard, Philadelphia, PA 29204 (Dr Weibel).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Measles-Mumps-Rubella and Varicella Vaccine Responses in Extremely Preterm Infants
D'Angio et al.
Pediatrics 2007;119:e574-e579.
ABSTRACT | FULL TEXT  

Preventing Varicella-Zoster Disease
Hambleton and Gershon
Clin. Microbiol. Rev. 2005;18:70-80.
ABSTRACT | FULL TEXT  

Partial Uptake of Varicella Vaccine and the Epidemiological Effect on Varicella Disease in 11 Day-Care Centers in North Carolina
Clements et al.
Arch Pediatr Adolesc Med 2001;155:455-461.
ABSTRACT | FULL TEXT  

Postlicensure Safety Surveillance for Varicella Vaccine
Wise et al.
JAMA 2000;284:1271-1279.
ABSTRACT | FULL TEXT  

Chickenpox Attributable to a Vaccine Virus Contracted From a Vaccinee With Zoster
Brunell and Argaw
Pediatrics 2000;106:28e-28.
ABSTRACT | FULL TEXT  

Vaccination of Children in Japan
Nishi et al.
Asia Pac J Public Health 1990;4:128-131.
ABSTRACT